Browsing by Author "Jaideep Reddy"

Now showing 1 - 5 of 5

Late-Onset Inflammatory Bowel Disease and Flares in Adenoviral and Inactivated Coronavirus Vaccine Recipients
(Lippincott Williams and Wilkins, 2024) Upinder Kaur; Dondapati Venkata Vamshi Krishna; Jaideep Reddy; Noti Taruni Srija Reddy; Amol Dehade; Sankha Shubhra Chakrabarti; Dawesh Prakash Yadav
[No abstract available]
Lecanemab: More Questions Than Answers!
(Adis, 2024) Upinder Kaur; Jaideep Reddy; Ashutosh Tiwari; Sasanka Chakrabarti; Sankha Shubhra Chakrabarti
The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer’s disease. Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer’s disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase III trials. However, there have been many questions raised over the clinical relevance of the otherwise minimal cognitive improvements. Furthermore, its rapid approval has been mired in controversy, in addition to the reports of adverse events such as amyloid-related imaging abnormalities and several deaths of participants in the lecanemab trials. Here, we analyze the evidence supporting lecanemab as an amyloid beta therapy and also discuss the concerns raised about its efficacy and safety. © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Patterns and determinants of drug-related neurological problems in older outpatients: An exploratory analysis of a six-year long observational study in North India
(Cambridge University Press, 2023) Upinder Kaur; Sankha Shubhra Chakrabarti; Jaideep Reddy; Amit Singh; Indrajeet Singh Gambhir
[No abstract available]
Patterns and outcomes of late onset thyroid disturbances after COVID-19 vaccination: A report of 75 cases
(John Wiley and Sons Inc, 2024) Upinder Kaur; Noti Taruni Srija Reddy; Jaideep Reddy; Dondapati Venkata Vamshi Krishna; Amol Dehade; Neeraj Kumar Agrawal
Isolated cases of subacute thyroiditis exist in the early period of COVID-19 vaccination, largely after mRNA vaccines. Here we report late onset thyroid disturbances and persistent health issues in patients of thyroid disorders after COVID-19 vaccination. Seventy-five patients with post COVID-19 vaccination thyroid disturbances were identified. Among these, 41 had flare of underlying thyroid illness, majority occurring at a median time lag of 28.4 weeks since 2nd dose. Thirty-one cases of new onset hypothyroidism and three of new onset hyperthyroidism were reported, with a median time lag respectively of 17.2 and 22.6 weeks since 2nd dose. Most cases occurred after ChAdOx1-nCoV-19, which was the commonest vaccine employed in mass roll out in India. Significant improvement was observed in majority, after a median follow up of 22–26 weeks. New onset health issues persisting for ≥4 weeks were reported in 37.3% and were common in individuals with history of COVID-19 before vaccine. New onset metabolic, musculoskeletal, and reproductive disorders were the common health complaints. Active monitoring is warranted for late onset adverse events after COVID-19 vaccines of all types. Larger studies with involvement of unvaccinated individuals are required to understand the incidence and causality of late onset thyroid disturbances after COVID-19 vaccines. © 2023 John Wiley & Sons Ltd.
Patterns, outcomes, and preventability of clinically manifest drug-drug interactions in older outpatients: a subgroup analysis from a 6-year-long observational study in North India
(Springer Science and Business Media Deutschland GmbH, 2025) Upinder Kaur; Jaideep Reddy; Noti Taruni Srija Reddy; Indrajeet Singh Gambhir; Ashish Kumar Yadav; Sankha Shubhra Chakrabarti
Older adults are vulnerable to adverse drug reactions (ADRs) and drug-drug interactions (DDIs). Evidence on clinically manifest DDIs in older outpatients is scanty. The present study aims to report clinically manifest DDIs, their risk factors, and preventive measures. A subgroup analysis of a 6-year (2015–2021) long prospective study was conducted in a tertiary hospital in North India. Older outpatients with ADRs constituted the study participants. Among 933 ADRs reported in 10,400 patient registrations, clinically manifest DDIs were involved in 199 (21.3%). DDIs accounted for 29.9%, 26.5%, and 21.3% of drug-related metabolic, vascular, and nervous system disorders, respectively. Movement disorders (n = 18), hypotension (n = 16), and hypoglycemia (n = 15) were the most common manifestations. Eighty-six percent of DDIs were of the pharmacodynamic type, and 13.1% were immune-mediated. Around 35% of DDIs resulted in hospitalization, with hyponatremia, movement disorder, and renal impairment as the common reasons. Older adults with Parkinsonism, infection, coronary artery disease, neuropsychiatric disease, and diabetes mellitus, respectively, had 3.28, 2.85, 1.97, 1.76, and 1.80 times higher odds of DDIs. Those receiving ≥ 10 drugs had 5.31 times higher odds of DDIs compared to individuals receiving 1–4 drugs. “Avoiding the causative drug,” “optimal monitoring of the patient,” and “start-low and go-slow” policy together could prevent 85% of DDIs. In conclusion, every fifth case of ADRs and nearly one third of ADR-related hospitalizations in older adults are related to DDIs. Movement disorder, hypotension, and hypoglycemia are the common manifestations. A holistic approach with drug omission, optimal patient monitoring, and slow titration of therapy can prevent significant DDIs in older adults. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.